Histogenics Corporation to Present at 5th Annual Cell & Gene Therapy Investor Day on April 27, 2017

WALTHAM, Mass., April 24, 2017 -- Histogenics Corporation (Histogenics) (Nasdaq:HSGX), a regenerative medicine company focused on developing and commercializing products in the musculoskeletal space, today announced that Adam Gridley, President & CEO, will present at the Alliance for Regenerative Medicine’s 5^th Annual Cell & Gene Therapy Investor Day on Thursday, April 27, 2017 at 2:15 pm ET in Boston.

In addition, Mr. Gridley will participate in a panel titled "Cell Therapy Beyond Oncology: Where Does The Greatest Potential Lie?" at 10:25 am ET.

A live video webcast of the presentation will be available at: http://www.arminvestorday.com/webcast. The webcast will be posted for further viewing on the event website following the conference.

About ARM's Cell & Gene Therapy Investor Day
Organized by the Alliance for Regenerative Medicine (ARM) and co-hosted with Piper Jaffray, this one-day, high impact program provides institutional, strategic and venture investors with unique insight into the financing hypothesis for advanced therapies-based treatment and tools.  The event includes clinical and commercial experts who are on-hand to address specific questions regarding the outlook for these products, as well as offer insight into how cell and gene therapies could impact the standard of care in key therapeutic areas such as cardiovascular disease, wound healing and tissue repair, ophthalmology, neurodegenerative diseases, diabetes and oncology.  The program will include talks by key opinion leaders in the industry, life science investment experts and analysts covering the sector as well as presentations by more than 30 leading companies from across the globe.  For more information, please visit www.arminvestorday.com.

About Histogenics Corporation
Histogenics is a leading regenerative medicine company developing and commercializing products in the musculoskeletal segment of the marketplace.  Histogenics’ regenerative medicine platform combines expertise in cell processing, scaffolding, tissue engineering, bioadhesives and growth factors to provide solutions to treat musculoskeletal-related conditions.  Histogenics’ first investigational product candidate, NeoCart, is currently in Phase 3 clinical development.  NeoCart is an autologous cell therapy designed to treat cartilage defects in the knee using the patient’s own cells.  Knee cartilage defects represent a significant opportunity in the United States, with an estimated 500,000 or more applicable procedures each year.  NeoCart is designed to exhibit characteristics of articular, hyaline cartilage prior to and upon implantation into the knee and therefore does not rely on the body to make new cartilage, characteristics not exhibited in other current treatment options.  For more information, please visit www.histogenics.com.

Contact:

Investor Relations
Tel: +1 (781) 547-7909
[email protected]